AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

Stock Information for Cognetivity Neurosciences Ltd

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cognetivity Neurosciences Ltd

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD(TM) 2025
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
AC Immune to Participate in Upcoming Investor Conferences
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease
AC Immune to Present at the Jefferies 2024 London Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.